The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Core Viewpoint - The article discusses a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA) following the disappointing results of its Alzheimer's drug candidate, simufilam, which led to a significant drop in the company's stock price [2][4]. Group 1: Allegations and Stock Performance - The complaint alleges that defendants provided misleading information regarding simufilam's efficacy in treating Alzheimer's Disease, expressing confidence in its performance [2]. - On November 25, 2024, Cassava announced that simufilam failed to meet all primary, secondary, and exploratory endpoints in its Phase 3 "ReThink-ALZ" study, underperforming against a placebo [2]. - Following the announcement, Cassava's stock plummeted from $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024, marking a decline of approximately 83.76% in just one day [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased SAVA shares during the specified class period (February 7, 2024, to November 24, 2024) are encouraged to register for potential lead plaintiff appointment, with a deadline set for February 10, 2025 [3][5]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [3].